Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV002422635 | SCV002680280 | likely pathogenic | Familial thoracic aortic aneurysm and aortic dissection | 2023-08-15 | criteria provided, single submitter | clinical testing | The p.C271W variant (also known as c.813C>G), located in coding exon 7 of the FBN1 gene, results from a C to G substitution at nucleotide position 813. The cysteine at codon 271 is replaced by tryptophan, an amino acid with highly dissimilar properties. The majority of FBN1 mutations identified to date have involved the substitution or generation of cysteine residues within cbEGF domains (Vollbrandt T et al. J Biol Chem. 2004;279(31):32924-32931). Internal structural analysis indicates that this alteration eliminates a structurally critical disulfide bond in cbEGF domain #01 (Ambry internal data). This particular cysteine substitution has been reported to segregate with disease in a family with thoracic aortic aneurysm and dissection (TAAD) as well as other clinical symptoms of Marfan syndrome (Regalado ES et al. Clin. Genet., 2016 06;89:719-23). An alteration in the same codon, p.C271G, has also been associated with Marfan syndrome (Groth KA et al. Genet. Med., 2017 07;19:772-777). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. |
| University of Washington Center for Mendelian Genomics, |
RCV000755188 | SCV000883017 | likely pathogenic | Congenital aneurysm of ascending aorta; Acute aortic dissection | 2016-01-20 | no assertion criteria provided | research |